

November 26, 2024

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Received Product Registration License for one product in Myanmar**

**Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that we, Zota Health Care Limited (the “Company”) have received product registration license for below mentioned product from the Ministry of Health Department of Food and Drug Administration, Myanmar:

<b>Sr. No.</b>	<b>Name of Product</b>	<b>Therapeutic Category</b>
1	S-AMLOZED 5 (Each uncoated tablet contains: S-Amlodipine Besilate eq. to S-Amlodipine 5mg)	Calcium Channel Blocker

We have received aforementioned product registration licenses for the validity period of five years; further the same can be renewed after expiration. The Company shall commence export of these products in Myanmar in a near term.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352